Predictors of Parkinson's disease dementia: Towards targeted therapies for a heterogeneous disease

Parkinsonism and Related Disorders

Volumn 20, Issue SUPPL.1, 2014, Pages

  Moore, Sarah F ^a   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Biomarkers; Dementia; Parkinson's disease; PD; PDD; Predictors

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; EPIDERMAL GROWTH FACTOR; GLUCOSYLCERAMIDASE; TAU PROTEIN; URIC ACID;

AGE; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; ARTICLE; BEHAVIOR DISORDER; BRAIN DISEASE; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIFFUSE LEWY BODY DISEASE; FLUENCY DISORDER; GENETIC RISK; GENETIC VARIABILITY; GLUCOCEREBROSIDASE GENE; HALLUCINATION; HUMAN; MICROTUBULE ASSOCIATED PROTEIN TAU GENE; MINI MENTAL STATE EXAMINATION; MUTATIONAL ANALYSIS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PARKINSON DISEASE DEMENTIA; POSITRON EMISSION TOMOGRAPHY; POSTURAL INSTABILITY AND GAIT DIFFICULTY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; RAPID EYE MOVEMENT SLEEP BEHAVIOR DISORDER; RISK ASSESSMENT; RISK FACTOR; TREMOR DOMINANT; URIC ACID BLOOD LEVEL;

BIOMARKERS; DEMENTIA; PARKINSON'S DISEASE; PD; PDD; PREDICTORS;

DEMENTIA; GLUCOSYLCERAMIDASE; HUMANS; PARKINSON DISEASE;

EID: 84887966412     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/S1353-8020(13)70026-9     Document Type: Article

References (31)

1. Levy G, Tang MX, Louis ED, Cote LJ, Alfaro B, Mejia H, et al. The association of incident dementia with mortality in PD. Neurology 2002, 59(11):1708-1713.
2. Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y, et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007, 22(12):1689-1707. quiz: 837.
3. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, et al. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013, 84(11):1258-1264.
4. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23(6):837-844.
5. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009, 132(Pt 11):2958-2969.
6. Compta Y, Parkkinen L, O'Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?. Brain 2011, 134(Pt 5):1493-1505.
7. Winder-Rhodes SE, Evans JR, Ban M, Mason SL, Williams-Gray CH, Foltynie T, et al. Glucocerebrosidase mutations influence the natural history of Parkinson's disease in a community-based incident cohort. Brain 2013, 136(Pt 2):392-399.
8. Burn DJ, Barker RA Mild cognitive impairment in Parkinson's disease: millstone or milestone?. Pract Neurol 2013, 13(2):68-69.
9. Litvan I, Goldman JG, Troster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012, 27(3):349-356.
10. Irwin DJ, Lee VM, Trojanowski JQ Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci 2013, 14(9):626-636.
11. Aarsland D, Kvaloy JT, Andersen K, Larsen JP, Tang MX, Lolk A, et al. The effect of age of onset of PD on risk of dementia. J Neurol 2007, 254(1):38-45.
12. Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D Changes in motor subtype and risk for incident dementia in Parkinson's disease. Mov Disord 2006, 21(8):1123-1130.
13. Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, et al. Cerebrospinal fluid amyloid-beta and phenotypic heterogeneity in de novo Parkinson's disease. J Neurol Neurosurg Psychiatry 2013, 84(5):537-543.
14. Compta Y, Pereira JB, Rios J, Ibarretxe-Bilbao N, Junque C, Bargallo N, et al. Combined dementia-risk biomarkers in Parkinson's disease: A prospective longitudinal study. Parkinsonism Relat Disord 2013, 19(8):717-724.
15. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351(24):2509-2518.
16. Chung KA, Lobb BM, Nutt JG, Horak FB Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010, 75(14):1263-1269.
17. Levy G, Jacobs DM, Tang MX, Cote LJ, Louis ED, Alfaro B, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002, 17(6):1221-1226.
18. Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendette M, Rios Romenets S, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: a prospective study. Mov Disord 2012, 27(6):720-726.
19. Nomura T, Inoue Y, Kagimura T, Nakashima K Clinical significance of REM sleep behavior disorder in Parkinson's disease. Sleep Med 2013, 14(2):131-135.
20. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol 2003, 60(3):387-392.
21. Stubendorff K, Aarsland D, Minthon L, Londos E The impact of autonomic dysfunction on survival in patients with dementia with Lewy bodies and Parkinson's disease with dementia. PLoS One 2012, 7(10):e45451.
22. Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, et al. CSF amyloid β 1-42 predicts cognitive decline in Parkinson disease. Neurology 2010, 75(12):1055-1061.
23. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol 2011, 10(3):230-240.
24. Chen-Plotkin AS, Hu WT, Siderowf A, Weintraub D, Goldmann Gross R, Hurtig HI, et al. Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 2011, 69(4):655-663.
25. Euser SM, Hofman A, Westendorp RG, Breteler MM Serum uric acid and cognitive function and dementia. Brain 2009, 132(Pt 2):377-382.
26. Duncan GW, Firbank MJ, O'Brien JT, Burn DJ Magnetic resonance imaging: a biomarker for cognitive impairment in Parkinson's disease?. Mov Disord 2013, 28(4):425-438.
27. Edison P, Ahmed I, Fan Z, Hinz R, Gelosa G, Ray Chaudhuri K, et al. Microglia, amyloid, and glucose metabolism in Parkinson's disease with and without dementia. Neuropsychopharmacology 2013, 38(6):938-949.
28. 11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008, 39(3):1027-1033.
29. Guo JL, Covell DJ, Daniels JP, Iba M, Stieber A, Zhang B, et al. Distinct alpha-synuclein strains differentially promote tau inclusions in neurons. Cell 2013, 154(1):103-117.
30. Sidransky E, Lopez G The link between the GBA gene and parkinsonism. Lancet Neurol 2012, 11(11):986-998.
31. Williams-Gray CH, Goris A, Saiki M, Foltynie T, Compston DA, Sawcer SJ, et al. Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol 2009, 256(3):493-498.